Swoop Granted Patent for Privacy by Design Data Processing Technique
Expands the use of artificial intelligence to positively influence health outcomes without sacrificing patient privacy
CAMBRIDGE, MA. – March 1, 2020 – Swoop, the company driving better patient outcomes through AI-generated digital audiences for the life sciences industry, today announced the grant of a patent for its privacy-safe sensitive data processing techniques. The patent uniquely positions the organization with the capability to ingest, manipulate and analyze sensitive information, such as health data, in a way that ensures privacy protection for individuals as well as solidifying its positive impact on patient outcomes and healthcare costs. This patent and the core concept of Privacy by Design that it embraces, is recognition that historical perspectives on privacy can and should evolve to be embedded into an organization’s architectural DNA.
“Though HIPAA has an enduring institutional legacy as a privacy law, we are experiencing a regulatory environment that is rapidly evolving. GDPR, CCPA, and self-regulatory bodies like the NAI, are all reconciling what consumer and patient privacy looks like in the digital world,” said Swoop co-founder and CTO Simeon Simeonov. “Our invention embodies the concept of Privacy by Design. Not only do we embrace privacy as the default state, but our patent outlines a de facto privacy architecture that maintains strict compliance as these and other privacy regulations and best practices develop.”
Patent No. 34933040, titled “High-Accuracy Data Processing and Machine Learning Techniques for Sensitive Data,” enables systematic compliance with the Health Insurance Portability and Accountability Act (HIPAA), the California Consumer Privacy Act (CCPA), the Network Advertising Initiative’s 2020 Code of Conduct, and the General Data Protection Regulation (GDPR).
“We specialize in protecting the privacy of individuals by performing disclosure risk assessments of our clients’ healthcare datasets,” said Jamie Blackport, CEO and Co-Founder of Mirador Analytics, which handles Swoop’s HIPAA compliance. “While working with Swoop to ensure HIPAA compliance, their commitment to developing systems with privacy in mind was clear and we have been impressed with the paramount importance they have placed on patient rights.”
“AI and big data are a potentially transformational, yet significantly untapped resource for healthcare,” says Swoop CEO and co-founder Ronald Elwell. “We are absolutely convinced that the power of data can save lives and improve outcomes, helping to reduce overall healthcare costs. Whether it is importing emerging and non-traditional Real-World Evidence data to help find undiagnosed rare disease patients, or creating custom NAI compliant DTC targeting segments, our system guarantees adherence with the growing number of privacy regulations, a statement we’re not convinced others can make.
“We’re proud to be on the leading edge of this revolution. Swoop has invested a tremendous amount of time and resources into expanding AI’s ability to positively influence health outcomes without sacrificing patient privacy, and we believe this patent represents a large step forward in our and the healthcare industry’s ability to do so.”
About Swoop Swoop empowers the world’s leading healthcare and life sciences organizations to better educate patients about disease states and the therapies that could effectively treat their conditions, as well as enable them to become active participants in their medical journey. Swoop’s HIPAA-certified and NAI-accredited system of engagement precisely engages ideal patient populations through cross-channel marketing strategies by utilizing granular-level longitudinal analytics, artificial intelligence and machine learning in conjunction with a real world data pool of over 300 million de-identified patients and a behavioral data stream of over 65 billion anonymous consumer transactions.
Media Contact John Seaner Chief Marketing Officer Swoop email@example.com +1 267-247-6323
Driving optimal patient outcomes through RWD-based and AI-generated digital audiences for the pharmaceutical industry.